Ask AI
Immunotherapy in Solid Tumor

CE / CME

Improving Outcomes With Immune Checkpoint Inhibitors for Solid Tumors

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: June 18, 2026

Expiration: December 17, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Fernandes MP, Oliveira C, Sousa H, Oliveira J. New approaches in early-stage NSCL management: potential use of PARP inhibitors and immunotherapy combination. Int J Mol Sci. 2023;24:4044.
  2. Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002-1014.
  3. Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40:586-597.
  4. Lavacchi D, Pellegrini E, Palmieri VE, et al. Immune checkpoint inhibitors in the treatment of renal cancer: current state and future perspective. Int J Mol Sci. 2020;21:4691.
  5. Atezolizumab [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2026.
  6. Avelumab [prescribing information]. Rockland, MA: EMD Serono, Inc.; 2024.
  7. Cemiplimab-rwlc [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2025.
  8. Cosibelimab-ipdl [prescribing information]. Waltham, MA: Checkpoint Therapeutics, Inc.; 2025.
  9. Dostarlimab-gxly [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2025.
  10. Durvalumab [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2025.
  11. Ipilimumab [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
  12. Nivolumab [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
  13. Pembrolizumab [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC; 2025.
  14. Retifanlimab-dlwr [prescribing information]. Wilmington, DE: Incyte Corporation; 2025.
  15. Tislelizumab-jsgr [prescribing information]. San Carlos, CA: BeiGene USA, Inc.; 2025.
  16. Toripalimab-tpzi [prescribing information]. Redwood City, CA: Coherus BioSciences, Inc.; 2025.
  17. Tremelimumab-actl [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2025.
  18. Andrews LP, Cillo AR, Karapetyan L, et al. Molecular pathways and mechanisms of LAG3 in cancer therapy. Clin Cancer Res. 2022;28:5030-5039.
  19. Nivolumab and relatlimab-rmbw [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
  20. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. v4.2026. nccn.org. Accessed May 29, 2026.
  21. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: melanoma: cutaneous. v1.2026. nccn.org. Accessed May 29, 2026.
  22. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: kidney cancer. v1.2026. nccn.org. Accessed May 29, 2026.
  23. Leonetti A, Wever B, Mazzaschi G, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat. 2019;46:100644.
  24. Attili I, Passaro A, Pavan A, et al. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): does biological rationale meet clinical needs? Crit Rev Oncol Hematol. 2017;119:30-39.
  25. Atezolizumab and hyaluronidase-tqjs [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2025.
  26. Nivolumab and hyaluronidase-nvhy [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
  27. Pembrolizumab and berahyaluronidase alfa-pmph [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC; 2025.
  28. Felip E, Burotto M, Zhou Y, et al. IMscin001 part 1: dose finding and pharmacokinetic study of subcutaneous atezolizumab in locally advanced or metastatic non-small-cell lung cancer and other solid tumors. Clin Pharmacol Drug Dev. 2021;10:1142-1153.
  29. Burotto M, Zvirbule Z, Mochalova A, et al. IMscin001 Part 2: a randomized phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. Ann Oncol. 2023;34:693-702.
  30. Burotto M, Zvirbule Z, Alvarez R, et al. Brief report: updated data from IMscin001 Part 2, a randomized phase III study of subcutaneous versus intravenous atezolizumab in patients with locally advanced or metastatic NSCLC. J Thorac Oncol. 2024;19:1460-1466.
  31. Felip E, Rojas CI, Schenker M, et al. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncol. 2025;36:775-785.
  32. Albiges L, Bourlon MT, Chacon M, et al. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Ann Oncol. 2025;36:99-107.
  33. Adamczyk J, George S, Bourlon MT, et al. Subcutaneous nivolumab maintains comparable efficacy and safety versus intravenous nivolumab in advanced clear cell renal cell carcinoma: updated results from CheckMate 67T. Presented at: Oncology Nursing Society Congress; April 9-13, 2025. Abstract 16944.
  34. Andre T, Shiu KK, Kim TW, et al. Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer. J Clin Oncol. 2021;39:Abstract 3500.
  35. Andre T, Elez E, Van Cutsem E, et al. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med. 2024;391:2014-2026.
  36. Overman MJ, Lenz H-J, Andre T, et al. Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 3510.
  37. Lenz HJ, Van Cutsem E, Luisa Limon M, et al. Neoadjuvant nivolumab-based immunotherapy in mismatch repair-deficient colon cancer. J Clin Oncol. 2022;40:161.
  38. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-1985.
  39. Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389:491-503.
  40. Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389:1672-1684.
  41. Cascone T, Awad MM, Spicer JD, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;391:1756-1769.
  42. Spicer JD, Garassino MC, Wakelee H, et al. Perioperative pembrolizumab plus neoadjuvant chemotherapy in early-stage non-small-cell lung cancer (KEYNOTE-671): event-free survival and pathological response in a randomized, double-blind, phase 3 trial. Lancet. 2024;404:1240-1252.
  43. Liberman M, Jones DR, Wakelee H, Gao S, et al. Clinical characteristics and surgical outcomes of patients receiving perioperative pembrolizumab in KEYNOTE-671. Ann Thorac Surg. 2026;121:281-289.
  44. Spicer JD, et al. Overall survival with perioperative pembrolizumab in resectable lung cancer. N Engl J Med. 2025;393:741.
  45. Forde PM, Spicer JD, Provencio M, et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med. 2025;393:741-752.
  46. de Gooyer PGM, Verschoor YL, van den Dungen LDW, et al. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial. Nat Med. 2024;30:3284
  47. Cercek A, Foote MB, Rousseau B, et al. Nonoperative management of mismatch repair-deficient tumors. N Engl J Med. 2025;392:2297.
  48. Gonugunta AS, von Itzstein MS, Gerber DE. Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report. J Med Case Rep. 2022;16:289.
  49. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217-1238.
  50. Hoffner B, Leighl NB, Davies M. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. Cancer Treat Rev. 2020;85:101979.
  51. Madden KM, Hoffner B. Ipilimumab-based therapy: consensus statement from the faculty of the Melanoma Nursing Initiative on managing adverse events with ipilimumab monotherapy and combination therapy with nivolumab. Clin J Oncol Nurs. 2017;21(suppl 4):30-41.
  52. Cheng AL, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab versus sorafenib in unresectable hepatocellular carcinoma: updated efficacy and safety results from IMbrave150. J Hepatol. 2022;76:862-873.
  53. Herbst RS, Arkenau HT, Santana-Davila R, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 2019;20:1109-1123.
  54. Herbst RS, Arkenau HT, Bendell J, et al. Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced non-small-cell lung cancer following disease progression on immunotherapy. J Thorac Oncol. 2021;16:289-298.
  55. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073
  56. Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35:3807-3814.
  57. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193-3198.
  58. Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785-792.